HK Stock MarketDetailed Quotes

02616 CSTONE PHARMA-B

Watchlist

2.720
+0.090+3.42%

Trading Dec 16 14:13 CST

3.49BMarket Cap-22.48P/E (TTM)

CSTONE PHARMA-B Key Stats

Cash Flow

All

YOY

Hide blank lines

(Q6)Jun 30, 2024

(FY)Dec 31, 2023

(Q6)Jun 30, 2023

(FY)Dec 31, 2022

(Q6)Jun 30, 2022

(FY)Dec 31, 2021

(Q6)Jun 30, 2021

(FY)Dec 31, 2020

(Q6)Jun 30, 2020

(FY)Dec 31, 2019

Turnover

-2.80%254.17M

-3.64%463.84M

-0.11%261.47M

97.51%481.36M

229.48%261.77M

-76.54%243.72M

--79.45M

--1.04B

----

Operating income

-2.80%254.17M

-3.64%463.84M

-0.11%261.47M

97.51%481.36M

229.48%261.77M

-76.54%243.72M

79.45M

1.04B

Cost of sales

23.97%-82.14M

21.40%-159.55M

-16.52%-108.04M

-90.00%-202.99M

-197.05%-92.72M

55.75%-106.83M

---31.22M

---241.42M

----

Operating expenses

23.97%-82.14M

21.40%-159.55M

-16.52%-108.04M

-90.00%-202.99M

-197.05%-92.72M

55.75%-106.83M

-31.22M

-241.42M

Gross profit

12.12%172.03M

9.31%304.3M

-9.23%153.44M

103.36%278.38M

250.46%169.04M

-82.83%136.89M

48.23M

797.41M

Selling expenses

52.25%-62.77M

39.09%-199.35M

10.19%-131.45M

10.03%-327.3M

-9.56%-146.35M

-155.92%-363.79M

-455.33%-133.58M

---142.15M

---24.06M

----

Administrative expenses

47.67%-46.67M

26.64%-182.71M

33.84%-89.19M

16.31%-249.06M

12.52%-134.82M

13.11%-297.6M

6.73%-154.11M

-0.30%-342.51M

1.55%-165.23M

-78.79%-341.48M

Research and development expenses

64.53%-66.25M

14.06%-527.8M

29.95%-186.77M

52.94%-614.16M

48.00%-266.63M

7.10%-1.3B

5.77%-512.75M

-0.65%-1.4B

-41.87%-544.15M

-64.15%-1.4B

Special items of operating profit

-45.26%27.71M

1,293.92%250.15M

151.54%50.62M

120.30%17.95M

203.48%20.12M

30.79%-88.42M

-131.15%-19.45M

77.63%-127.75M

109.12%62.43M

24.06%-571.04M

Operating profit

111.83%24.05M

60.25%-355.42M

43.30%-203.35M

53.38%-894.2M

53.52%-358.63M

-57.24%-1.92B

-15.00%-771.65M

47.16%-1.22B

45.70%-671.01M

-28.72%-2.31B

Financing cost

-42.13%-8.35M

-39.42%-11.82M

-100.07%-5.87M

-278.10%-8.48M

-33.64%-2.94M

-69.85%-2.24M

-823.11%-2.2M

-335.64%-1.32M

-59.73%-238K

---303K

Earning before tax

107.50%15.7M

59.32%-367.23M

42.13%-209.23M

52.99%-902.68M

53.28%-361.57M

-57.26%-1.92B

-15.29%-773.85M

47.11%-1.22B

45.68%-671.24M

-28.74%-2.31B

After-tax profit from continuing operations

107.50%15.7M

59.32%-367.23M

42.13%-209.23M

52.99%-902.68M

53.28%-361.57M

-57.26%-1.92B

-15.29%-773.85M

47.11%-1.22B

45.68%-671.24M

-28.74%-2.31B

Earning after tax

107.50%15.7M

59.32%-367.23M

42.13%-209.23M

52.99%-902.68M

53.28%-361.57M

-57.26%-1.92B

-15.29%-773.85M

47.11%-1.22B

45.68%-671.24M

-28.74%-2.31B

Profit attributable to shareholders

107.50%15.7M

59.32%-367.23M

42.13%-209.23M

52.99%-902.68M

53.28%-361.57M

-57.26%-1.92B

-15.29%-773.85M

47.11%-1.22B

45.68%-671.24M

-32.27%-2.31B

Basic earnings per share

105.88%0.01

62.34%-0.29

45.16%-0.17

53.33%-0.77

53.73%-0.31

-41.03%-1.65

-1.52%-0.67

51.05%-1.17

-148.89%-0.66

14.34%-2.39

Diluted earnings per share

105.88%0.01

62.34%-0.29

45.16%-0.17

53.33%-0.77

53.73%-0.31

-41.03%-1.65

-1.52%-0.67

51.05%-1.17

-148.89%-0.66

14.34%-2.39

Currency Unit

CNY

Accounting Standards

IAS

Audit Opinions

Unqualified Opinion

Auditor

Deloitte Guan Huang Chen Fang Certified Public Accountants

	(Q6)Jun 30, 2024	(FY)Dec 31, 2023	(Q6)Jun 30, 2023	(FY)Dec 31, 2022	(Q6)Jun 30, 2022	(FY)Dec 31, 2021	(Q6)Jun 30, 2021	(FY)Dec 31, 2020	(Q6)Jun 30, 2020	(FY)Dec 31, 2019
Turnover	-2.80%254.17M	-3.64%463.84M	-0.11%261.47M	97.51%481.36M	229.48%261.77M	-76.54%243.72M	--79.45M	--1.04B	----	----
Operating income	-2.80%254.17M	-3.64%463.84M	-0.11%261.47M	97.51%481.36M	229.48%261.77M	-76.54%243.72M	79.45M	1.04B
Cost of sales	23.97%-82.14M	21.40%-159.55M	-16.52%-108.04M	-90.00%-202.99M	-197.05%-92.72M	55.75%-106.83M	---31.22M	---241.42M	----	----
Operating expenses	23.97%-82.14M	21.40%-159.55M	-16.52%-108.04M	-90.00%-202.99M	-197.05%-92.72M	55.75%-106.83M	-31.22M	-241.42M
Gross profit	12.12%172.03M	9.31%304.3M	-9.23%153.44M	103.36%278.38M	250.46%169.04M	-82.83%136.89M	48.23M	797.41M
Selling expenses	52.25%-62.77M	39.09%-199.35M	10.19%-131.45M	10.03%-327.3M	-9.56%-146.35M	-155.92%-363.79M	-455.33%-133.58M	---142.15M	---24.06M	----
Administrative expenses	47.67%-46.67M	26.64%-182.71M	33.84%-89.19M	16.31%-249.06M	12.52%-134.82M	13.11%-297.6M	6.73%-154.11M	-0.30%-342.51M	1.55%-165.23M	-78.79%-341.48M
Research and development expenses	64.53%-66.25M	14.06%-527.8M	29.95%-186.77M	52.94%-614.16M	48.00%-266.63M	7.10%-1.3B	5.77%-512.75M	-0.65%-1.4B	-41.87%-544.15M	-64.15%-1.4B
Special items of operating profit	-45.26%27.71M	1,293.92%250.15M	151.54%50.62M	120.30%17.95M	203.48%20.12M	30.79%-88.42M	-131.15%-19.45M	77.63%-127.75M	109.12%62.43M	24.06%-571.04M
Operating profit	111.83%24.05M	60.25%-355.42M	43.30%-203.35M	53.38%-894.2M	53.52%-358.63M	-57.24%-1.92B	-15.00%-771.65M	47.16%-1.22B	45.70%-671.01M	-28.72%-2.31B
Financing cost	-42.13%-8.35M	-39.42%-11.82M	-100.07%-5.87M	-278.10%-8.48M	-33.64%-2.94M	-69.85%-2.24M	-823.11%-2.2M	-335.64%-1.32M	-59.73%-238K	---303K
Earning before tax	107.50%15.7M	59.32%-367.23M	42.13%-209.23M	52.99%-902.68M	53.28%-361.57M	-57.26%-1.92B	-15.29%-773.85M	47.11%-1.22B	45.68%-671.24M	-28.74%-2.31B
After-tax profit from continuing operations	107.50%15.7M	59.32%-367.23M	42.13%-209.23M	52.99%-902.68M	53.28%-361.57M	-57.26%-1.92B	-15.29%-773.85M	47.11%-1.22B	45.68%-671.24M	-28.74%-2.31B
Earning after tax	107.50%15.7M	59.32%-367.23M	42.13%-209.23M	52.99%-902.68M	53.28%-361.57M	-57.26%-1.92B	-15.29%-773.85M	47.11%-1.22B	45.68%-671.24M	-28.74%-2.31B
Profit attributable to shareholders	107.50%15.7M	59.32%-367.23M	42.13%-209.23M	52.99%-902.68M	53.28%-361.57M	-57.26%-1.92B	-15.29%-773.85M	47.11%-1.22B	45.68%-671.24M	-32.27%-2.31B
Basic earnings per share	105.88%0.01	62.34%-0.29	45.16%-0.17	53.33%-0.77	53.73%-0.31	-41.03%-1.65	-1.52%-0.67	51.05%-1.17	-148.89%-0.66	14.34%-2.39
Diluted earnings per share	105.88%0.01	62.34%-0.29	45.16%-0.17	53.33%-0.77	53.73%-0.31	-41.03%-1.65	-1.52%-0.67	51.05%-1.17	-148.89%-0.66	14.34%-2.39
Currency Unit	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY
Accounting Standards	IAS	IAS	IAS	IAS	IAS	IAS	IAS	IAS	IAS	IAS
Audit Opinions	--	Unqualified Opinion	--	Unqualified Opinion	--	Unqualified Opinion	--	Unqualified Opinion	--	Unqualified Opinion
Auditor	--	Deloitte Guan Huang Chen Fang Certified Public Accountants	--	Deloitte Guan Huang Chen Fang Certified Public Accountants	--	Deloitte Guan Huang Chen Fang Certified Public Accountants	--	Deloitte Guan Huang Chen Fang Certified Public Accountants	--	Deloitte Guan Huang Chen Fang Certified Public Accountants

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Heat List

Overall

No Data

Investment Theme

Pharmaceutical Companies

Intraday-2.25%

02616 CSTONE PHARMA-B

CSTONE PHARMA-B Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow